News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accentia Biopharmaceuticals (ABPI) Announces that FDA Grants Orphan Drug Status for Revimmune(TM) Therapy for the Prevention of Graft-Versus-Host Disease in Bone Marrow Transplant


9/14/2011 9:20:40 AM

TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI) and its majority-owned subsidiary, Biovest International, Inc. (OTCQB:BVTI), today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune™, the Company’s proprietary system-of-care based on high-dose administration of Cytoxan® (cyclophosphamide), for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant. GVHD is a life-threatening autoimmune complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted cells trigger an immune attack on the transplant recipient's body.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES